加载中
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
常规交易时段
US$3.305
−US$0.155 · -4.48%
盘中时间采用ET。市场数据可能有所延迟。
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
日内区间
当前US$3.305
52周区间
当前US$3.305
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
53
合理估值
情绪
64
看涨
风险
58
风险偏高
动量
28
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
日内区间
当前US$3.305
52周区间
当前US$3.305
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$13.50
上涨空间 308.47%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM1262.01万0.02%787.4亿 USD0.19%US$278.18-0.27%
Vanguard Extended Market ETFVXF868.43万0.01%954亿 USD0.05%US$233.89-0.47%
State Street SPDR S&P Pharmaceuticals ETFXPH593.83万1.29%4.62亿 USD0.35%US$64.195-0.70%
iShares Biotechnology ETFIBB434.52万0.04%108.2亿 USD0.44%US$204.41-1.01%
Vanguard Russell 2000 ETFVTWO388.6万0.02%180亿 USD0.06%US$112.37-0.26%
Schwab U.S. Small-Cap ETFSCHA272.32万0.01%218.24亿 USD0.03%US$32.715-0.23%
Dimensional - US Small Cap ETFDFAS266.46万0.01%338.69亿 USD0.31%US$78.37+0.03%
Vanguard Health Care ETFVHT193.87万0.01%220亿 USD0.09%US$319.63+0.19%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
